B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of growth arrested clonal B lymphocytes that undergo apoptosis when treated with fludarabine. To further explore the mechanism for the cell cycle arrest, we examined the expression and activity of cyclin-dependent kinases and inhibitors in primary B-CLL cells. We observed high levels of p27kip1, cyclin D2, cyclin E, cdk2, and cdk4 expression in freshly isolated B-CLL cells. Despite high levels of cyclins and cdks, little cdk2 or cdk4 activity was observed with p27kip1 in complex with cyclinD2/cdk4 and cyclin E/cdk2. Remarkably, when B-CLL cells were treated in vitro with fludarabine, p27kip1 underwent caspase-specific degradation accompanied by an increase in cdk4 activity. We conclude that the G0/G1 arrest of B-CLL cells may protect against apoptosis and that the decrease in p27kip1 expression by caspase cleavage may be a key step in chemotherapy-induced apoptosis in B-CLL.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a malignant disorder characterized by the gradual accumulation of growtharrested clonal mature B-lymphocytes. Cytometry analysis has consistently revealed that o5% of B-CLL cells are proliferating. In addition to the growth defect, B-CLL cells are generally resistant to apoptosis. 1 Expression of several apoptosis-regulating proteins have been tested in B-CLL, but none of them proved unambiguously correlated to disease progression or drug sensitivity. [2] [3] [4] p27kip1 is highly expressed in B-CLL and high expression of p27kip1 is an adverse prognostic factor in B-CLL. 5 The cyclindependent kinase inhibitor p27kip1 plays a major role in G0/G1 cell cycle arrest. 6, 7 p27kip1 binds to cyclin D/cdk4 complexes and inhibits kinase activity. Increased cyclin D and decreased p27kip1 expression leads to cyclin D/cdk4 kinase activity as well as cyclin E/cdk2 activity. 8, 9 High expression of p27kip1 facilitates exit from the cell cycle and entry into a quiescent state, while downregulation of p27kip1 permits entry into the cycle. 10, 11 The level of p27kip1 expression appears critical for oncogenesis, loss of one copy of p27kip1 may be sufficient to contribute to cancer. 12 In addition, low levels of p27kip1 expression may be indicative of poor prognosis in various cancers. 7, 13 For example, in certain lymphoid malignancies p27kip1 expression was found to be lower in rapidly proliferating cases. 14 B-CLL cells can be isolated from patients and kept in culture for several days. We have observed an increased survival in vitro of B-CLL cells expressing high p27kip1 level compared to the reduced survival with spontaneous apoptosis of cells that expressed low p27kip1 levels. 5 Interleukin-4, which promotes B-CLL survival, maintained elevated p27kip1 expression in B-CLL. An antiapoptotic role for p27kip1 has been recently suggested in other models: p27kip1 null fibroblasts were found to undergo increased apoptosis following serum deprivation and restoration of p27kip1 levels of expression in these cells rescued them from undergoing apoptosis. 15 These observations led us to hypothesize that p27kip1 expression could be correlated to the apoptotic response.
Fludarabine is a purine nucleoside analog and consequently has a cell cycle-specific cytotoxicity requiring DNA synthesis. In actively dividing cells, incorporation of fludarabine into replicating DNA inhibits further chain elongation and induces apoptosis from S phase. In nonproliferating cells such as B-CLL, it is not clearly understood how fludarabine induces apoptosis. Several recent studies have suggested that caspase activation might play an important role in fludarabine-induced toxicity observed in quiescent cells. 16, 17 Caspase activation is a key event in the regulation of the execution phase of apoptosis. Caspases participate in the cleavage of several cell cycle regulatory proteins such as retinoblastoma protein and the cdk inhibitors p21Cip1 and p27kip1. [18] [19] [20] To better define the cell cycle arrest observed in primary B-CLL, we examined the expression of various cyclin-dependent kinases and inhibitors. We observed that nearly all B-CLL cells expressed high levels of cyclin D2, cyclin E, cdk2, cdk4 as well as p27kip1. Little cdk activity was observed. Upon fludarabine treatment, p27kip1 underwent a rapid caspase-dependent cleavage followed by a rapid apoptotic response. Despite cdk activation, there was little evidence for cell cycle progression. These results support the notion that p27kip1 plays an important role in preventing cell cycle advancement and apoptosis in B-CLL.
Material and methods

Cell isolation and culture
Peripheral blood from patients with chronic B-CLL was obtained after informed consent. Blood mononuclear cells were isolated by Ficoll-Hypaque density gradient and monocytes removed by plastic adherence. B and T lymphocytes from normal healthy donors were separated by sheep erythrocyte rosetting.
For some experiments, freshly isolated cells were cultured at a final concentration of 2 Â 10 6 /ml in RPMI 1640 containing 10% heat-inactivated fetal calf serum (FCS), glutamine 2 mM, penicillin 50 U/ml and streptomycin 50 mg/ml at 371C in a 5% CO 2 humidified atmosphere. Normal T lymphocytes were stimulated with phorbol myristate acetate (PMA) 1 ng/ml (Sigma, St Louis, MO, USA) and phytohemagglutinin (PHA) 10 mg/ml (Sigma, France). B-CLL cells were cultured for 48 h in medium alone or added with fludarabine (5 Â 10 À6 M).
Protein extracts
Whole-cell protein extracts were prepared by lysing 1-2 Â 10 7 cells in RIPA buffer (10 mM Tris pH 7.5, 150 mM NaCl, 1% NP40, 0.1% SDS, 1% deoxycholic acid, 1 mM Na-orthovanadate, 1 mM NaF, 100 mg/ml phenylmethylsulfonyl fluoride/ PMSF/, 10 mg/ml leupeptin and 10 mg/ml aprotinin) for 30 min on ice. Lysates were centrifuged at 12 000 r.p.m for 15 min and supernatant collected. Protein concentration was assessed by the Bio-Rad assay method (Bio-Rad Laboratories, Richmond, CA, USA).
Preparation of cytoplasmic and nuclear extracts: 5 Â 10 7 cells were dispersed in 500 ml cytoplasmic buffer containing 10 mM Hepes (pH ¼ 7.6), 0.1% NP40, 0.1 mM EDTA and protease inhibitors for 5 min. Samples were vortexed for 10 s and spun down 5 min at 400 r.p.m. The cytoplasmic extracts were present in the supernatant. The nuclear extracts were obtained from the remaining pellets by applying the same protocol as for wholecell extracts.
Western blotting
Equal amounts of protein (50 mg) were electrophoresed in a 12 or 7.5% SDS-polyacrylamide gel and transferred onto a polyvinylidene difluoride membrane (Immobilon-P, Millipore, Bedford, MA, USA). Loading was controlled by membrane staining with Naphthol Blue Black (Sigma, France). Membranes were blocked for 1 h in 5% nonfat dry milk phosphate-buffered saline (PBS) and incubated for 1 h with the following antibodies: mouse antihuman pRb (G3-245, 0.5 mg/ml), p21 (6B6, 0.5 mg/ ml), cyclin D2 (G132-43, 2 mg/ml), all from PharMingen International (Becton Dickinson, France); rabbit antihuman p130 (C-20), cyclin E (C-19), cyclin D3 (C-16) and Nterminal-p27kip1 (N-20), all in concentration 0.5 mg/ml (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were subsequently washed twice in buffer containing 10 mM Tris pH 8.0, 200 mM NaCl and 0.1% Tween and incubated with an appropriate horseradish peroxidase-linked secondary antibody at a 1:5000 or 1:10 000 dilution for 1 h. After three washings in the buffer, signals were detected by an enhanced chemoluminescent system (ECL, Amersham, Buckinghamshire, UK).
Immunoprecipitation
Protein extracts of 1 mg were incubated with anticyclin D2 antibody (G132-43), or 5 mg anti-cdk4 antibody (68456E), both from Pharmingen, in 1 ml lysis buffer for 2 h at 41C; followed by incubation with protein A Sepharose beads for 30 min. For anticdk2 immunoprecipitation, 5 mg anti-cdk2 agarose conjugated antibody (M2) (Santa Cruz, CA, USA) were used. After a 2 min centrifugation at 12 000 r.p.m., the supernatants were removed and stored for further Western blotting analysis. The beads were washed three times with lysis buffer and complexes resuspended into loading buffer (Tris HCl pH 6.8 100 mM, glycerol 12.5%, bmercaptoethanol 8%, bromophenol blue 0.1%, SDS 3%). Immunocomplexes were harvested and subjected to Western blotting with appropriate antibodies.
Cdk kinase activity assay
A total of 300 mg of the protein extract as immunoprecipitated with 2 mg of mouse anti-Cdk2 antibody (D-12, Santa Cruz) for 2 h at 41C and then incubated for 1 h with 20 ml of mouse immunoglobulin G-Sepharose (Protein G PLUS-Agarose, Santa Cruz). Immunocomplexes were harvested by centrifugation, washed three times with RIPA buffer containing Na-orthovanadate 1 mM, and NaF 10 mM, twice with RIPA-buffer without SDS and inhibitors and resuspended in 20 ml kinase buffer (20 mM Tris pH 7.5, 4 mM MgCl 2 ). Each immunoprecipitate was incubated with 5 mg of histone H1 (Boehringer, Mannheim, Germany) for cdk2 activity or 1 mg of recombinant pRb for cdk4 activity, 15 nM of ATP (Sigma, France) and 10 mCi of [g- 
Multiprobe RNase protection assay
A series of templates including, p27kip1 and GAPDH were purchased from Pharmingen. The templastes were used for the T7 polymerase-directed synthesis of a high specific activity, 32P-labeled antisense RNA probe set. Hybridization, digestion of ssRNA, purification, and revelation of RNase protected probes were made according to the manufacturer's instructions of the RiboQuant kit (Pharmingen).
MTT assay
Cell viability after drug exposure was assessed by MTT test. B-CLL lymphocytes (4 Â 10 5 cells/well) were incubated in 96-well plates in a final volume of 200 ml. After 48 h, 20 ml of MTT was added to each well for a further 6 h. The precipitate was dissolved in 200 ml DMSO and the absorbance values at 550 nm were determined on a multiwell plate reader. Each condition was repeated in eight wells, and the result expressed as the mean of the eight wells. The control condition was a 2-day incubation of the cells in the medium alone, and the viability expressed as the percentage with respect to this control.
TUNEL assay
A total of 1 Â 10 5 cells were fixed in 10% neutral buffered formalin for 15 min and spun down on slides. Slides were incubated in methanol at À201C for 5 min and TUNEL reaction mixture was added according to the manufacturer's instruction (Boehringer Mannheim). Revelation was made with alkaline phosphatase substrate solution (Vector Laboratories, Burlingame, CA, USA).
Results
Expression of cyclins, cdks, and inhibitors in B-CLL
We have shown previously that cyclin D2 mRNA was frequently overexpressed in B-CLL cells. 21 To determine if cyclin D2 protein was also overexpressed, we performed Western blots with a specific cyclin D2 antibody in 30 B-CLL samples. As shown in Figure 1 , cyclin D2 protein expression was present in 28/30 samples and higher when compared to B lymphocytes. In addition, 27/30 B-CLL samples also had detectable levels of cyclin E. In B-CLL cells, cdk4 was also consistently expressed in all samples (Figure 1 ).
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To determine if cyclins formed complexes, we performed immunoprecipitations with anti-cdk4 or anti-cdk2 antibodies followed by Western blotting with anticyclin D2 or anticyclin E antibody, respectively. As illustrated in Figure 2a , cyclin D2-cdk4 complexes as well as low amounts of cyclin E-cdk2 complexes were observed in 10 freshly harvested unstimulated B-CLL cells.
We have shown previously that the cdk inhibitor p27kip1 was over-expressed in most B-CLL samples. 5 The presence of p27kip1 in cyclin D-cdk4 complexes was studied by Western blotting after immunoprecipitation for either cyclin D2 or cdk4. The p27kip1 protein was found in association with cdk4 and cyclin D2. Similarly, p27kip1 was present in cyclin E-cdk2 complexes when immunoprecipitated by anti-cdk2 antibodies. To determine whether p27kip1 was in excess, extracts were first immuno-depleted with either anticyclin D2 or anti-cdk2 immunoprecipitation, then blotted for p27kip1. As shown in Figure 2b , after D2 or cdk2 were immuno-depleted, a significant level of p27kip1 remained in the lysate, suggesting that p27kip1 protein levels were present in excess required to completely bind the cyclin/cdk complexes. Other cdk inhibitors, including INK4 family members and p21 were not detected in B-CLL cells (data not shown).
To determine if the cyclin-cdk complexes were catalytically active, immunoprecipitates with cdk2 or cdk4 antibody were prepared from 10 B-CLL samples. The cdk4 kinase activity was determined by assaying anti-cdk4 immunoprecipitates with GST-pRb as a substrate. Cdk4 activity was undetectable in all B-CLL cells, while it was readily detectable in normal stimulated lymphocytes. Similarly, anti-cdk2 immunoprecipitates had little kinase activity in B-CLL cells when using Histone H1 as a substrate (Figure 2c ).
Subcellular localization of cyclin/cdks and inhibitors
B-CLL cells typically are in a growth-arrested state with o5% of the total circulating population present in S phase. Given that we detected significant levels of cyclins and cdks in B-CLL cells, it was unclear why more cells were not proliferating. To examine the subcellular distribution of the cyclin/cdks, nuclear and cytoplasmic extracts of B-CLL cells were prepared. Antibodies against b-tubulin and Sp1 were used as controls for the cytoplasmic and the nuclear extraction, respectively. Cross contamination appeared to be o10% (Figure 3a) . In fresh B-CLL cells from 12 different samples, cyclin D2 was predominantly cytoplasmic while cdk4 appeared present in both cytoplasmic and nuclear compartments. Notably, p27kip1 appeared to be present in large amounts in both cytoplasmic and nuclear extracts. In contrast, Cdk2 appeared predominantly cytoplasmic, while cyclin E was strictly nuclear (Figure 3a) , perhaps Immunoprecipitates from B-CLL cells were prepared using either an antibody against cdk4 or an antibody against cdk2, cdk4, and cdk2 kinase activities were determined using GST-pRb and histone H1 as substrates, respectively. Extracts from 24 h stimulated T cells are shown as positive control. The median cdk4 activity of the 10 B-CLL samples was 0.670.3 as compared to resting T lymphocytes (T0). The median cdk2 activity of the 10 CLL samples tested was 1.470.7 as compared with T0 cells. In vitro exposure to fludarabine induces a decrease in p27kip1 expression
In vitro treatment of B-CLL cells results in apoptosis. 4 To determine the effect of pharmacological concentrations of fludarabine (5 Â 10 À6 M) on B-CLL, 35 samples of fresh B-CLL cells were assessed by MTT. 22 Viability was reduced from 100 to 55723% when treated for 48 h compared to treatment with medium alone. p27kip1 expression was determined before and after fludarabine treatment. Notably, there was no correlation between the baseline level of p27kip1 expression and the sensitivity to fludarabine-induced apoptosis, suggesting that the level of p27kip1 expression was not predictive of the in vitro sensitivity to fludarabine. In the 26 cases in which substantial apoptosis was observed (o60% viability by MTT), there was a decrease in p27kip1 expression. Conversely, in the nine cases exhibiting little or no apoptosis (over 70% viability by MTT after 48 h exposure to fludarabine), p27kip1 level of expression remained unchanged. Hence, the decrease in p27kip1 expression was significantly correlated to the extent of in vitro apoptosis (Figure 3b ).
Caspase-dependent cleavage of p27kip1
Given the dramatic decrease in p27kip1 levels in response to fludarabine treatment, we considered the possibility that p27kip1 itself was subject to cleavage by caspases. p27kip1 expression was dramatically decreased when Western blotted with a polyclonal antibody (C-19) raised against the C-terminal part of p27kip1 (amino acids 181-198). In contrast, when using a polyclonal antibody (N-20) raised against the N-terminal part of p27kip1 (amino acids 2-21), a faster migrating protein, with an apparent molecular weight of 23 kDa (p23), was detected in all 25 samples where a significant degree of apoptosis was observed (Figure 4a) . The same blots were re-exposed to an antip21 antibody to rule out the possibility of crossreactivity of p27kip1 antibody with p21 (data not shown).
The p23 protein was never detected in extracts prepared from freshly isolated B-CLL cells and remained undetectable when cells were incubated with IL4, a known survival factor. Occasionally, p23 were detected in cells cultured in medium alone for more than 12 h, but only when some spontaneous apoptosis was confirmed by TUNEL assay (data not shown). The increase in p23 level of expression paralleled the percentage of apoptotic cells after fludarabine exposure. The p23 fragment was also detected when B-CLL cells were exposed to other proapoptotic drugs including corticosteroids or 2-chloro-desoxyadenosine (2-CDA) (data not shown). p23 was also detected in normal B and T lymphocytes after fludarabine exposure, concomitantly with the occurrence of apoptosis (data not shown). Therefore, appearance of p23 was not restricted to fludarabine-induced apoptosis of B-CLL cells, but appears to be present as a general feature during apoptosis.
To rule out the possibility that the decrease in p27kip1 expression in response to fludarabine, was as a result of a decrease in p27kip1 mRNA expression, RNase protection assay was performed. No significant changes in p27kip1 mRNA levels were detected (Figure 4b ).
p23 is a caspase cleaved form of p27kip1
Scanning the peptide sequence for human p27kip1 revealed a candidate caspase consensus cleavage sequence (D 136 -PSD 139 ). 23 If p27kip1 was cleaved at this site, then the expected truncated N-terminal form is approximately 23 kDa. To determine if caspases were active in the generation of p23, B-CLL cells were incubated with caspase inhibitors prior to fludarabine exposure. Samples were preincubated for 1 h with either z-VAD-fmk (50 mM), a general caspase inhibitor, or ac-DEVD-CHO (100 mM), a specific inhibitor of caspase-3 followed by exposed to fludarabine for 24-48 h. In samples pretreated with caspase inhibitors, the percentage of apoptotic cells was drastically reduced. In addition, the p23 fragment was no longer detected when preincubated with either caspase inhibitor and there was no decrease in p27kip1 expression (Figure 4c ). Incubation with Z-AAD-CMK (50 mM), a specific granzyme inhibitor, did not prevent apoptosis nor apparition of p23 fragment in the presence of fludarabine (data not shown).
p27kip1 cleavage is an early event as compared to pRb cleavage
The degree of caspase-3 activation after exposure to fludarabine was evaluated by PARP cleavage. In three B-CLL samples with in vitro sensitivity to fludarabine previously confirmed, we p27kip1 cleavage during apoptosis of B-CLL cells L Sanhes et al assessed both PARP and p27kip1 cleavage. PARP cleavage was detected after 6-h exposure, as evidenced by the appearance of the 89 kDa cleavage product. The p23-truncated form of p27kip1 was also detectable 6 h after fludarabine exposure (Figure 4d ). Neither p23 nor PARP cleavage was detected before that time point (data not shown).
pRb has been reported to undergo specific cleavage by caspases during the apoptotic response. 24 Fludarabine-treated B-CLL cells were Western blotted with a specific pRb antibody. A truncated form of pRb, with a 100 kDa molecular weight, was initially detected followed by the disappearance of the fulllength pRb protein and further cleavage into two fragments of 68 and 42 kDa. Notably, pRb cleavage appeared several hours after p27kip1 and PARP cleavage. The 100 kDa form was detected after exposure to fludarabine for 24 h, while the subsequent cleavage to 42 and 68 kDa fragments was apparent after 72 h (Figure 4d ).
Cdk-4 activity increases but does not induce cell cycle progression after fludarabine
Given the possibility that B-CLL contained inactive cyclin/Cdk complexes due to p27kip1, we considered the possibility that fludarabine-induced cleavage of p27kip1 might result in the activation of cyclin/cdk activity. Lysates from 10 untreated or fludarabine-exposed B-CLL cells were tested for cdk4 activity with GST-pRb and for cdk2 activity with histone H1. Although Cdk2 activity remained undetectable, cdk4 activity increased after fludarabine treatment, reaching a level comparable to that observed in mitogen-stimulated lymphocytes. Moreover, in all samples tested, cdk4 increased activity was strictly correlated with the appearance of p23. Notably, cdk4 activity was observed in one untreated control sample, but in this case p23 was also clearly detectable ( Figure 5a ). Given that fludarabine treatment led to an increase in cdk4 activity, we tested whether there was evidence for entry into the cell cycle. Using global techniques such as Ki67 staining, BrDU labeling, and PI staining, we were unable to detect any cell cycle progression in B-CLL cells with evidence for appearance of p23 after fludarabine exposure (data not shown). In addition, pRb and p130 phosphorylation status was examined to determine if they were phosphorylated in response to increasing cdk4 activity in vivo. Prior to fludarabine treatment, pRb protein was present in its hypophosphorylated form and p130 appears in its growth arrested state. 25 After fludarabine exposure, no changes in pRb or p130 phosphorylation state were detected.
Cdk4 activity appears restricted to the cytoplasm
To address the failure of cell cycle progression despite cleavage of p27kip1 and activation of cdk4 kinase activity, we studied the subcellular localization of these factors. After fludarabine exposure, cdk4 became undetectable in the nuclear fraction, and was exclusively localized in the cytoplasm. The p27kip1 protein was found to be present in both nuclear and cytoplasmic extracts, while the p23 fragment was detected exclusively in cytoplasmic extracts suggesting that p27kip1 was cleaved only in the cytoplasm and remained intact in the nucleus.
Cytoplasmic and nuclear extracts were immunoprecipitated with anti-cdk4 antibody and tested for kinase activity using recombinant pRb as a substrate. All the detectable cdk-4 activity after fludarabine exposure was present exclusively in the cytoplasmic extracts (Figure 5b) .
To determine if p23 could form complexes with cdk4, we performed immunoprecipitations of fludarabine-treated wholecell extracts with anti-cdk4 antibody followed by Western blotting with the N-terminal p27kip1 antibody. After 24 h fludarabine exposure, cdk4 was observed to be in complex with both p27kip1 and p23, while after a 48 h exposure, p23 was almost exclusively present (Figure 5c ). To explore the mechanism for the apparent cell cycle arrest, we examined the expression and activity of G1 cyclin-dependent kinases in primary B-CLL cells. We observed a nearly uniform overexpression of cyclin D2, cyclin E and cdk4 compared with normal resting lymphocytes. However, despite high levels of expression, there was little cdk4 or cdk2 activity. The high level of p27kip1 expression observed in B-CLL cells is likely to play a major role in this cell cycle arrest, as the function of p27kip1 is strongly linked to the control of cell cycle entry. 26, 27 We observed that p27kip1 was present in large amounts in B-CLL cells and contained within cyclin D2-cdk4 and cyclin E-cdk2 complexes.
In neural precursor cell cycle regulation, it has been shown that kinase inactive cdk4 mutants could arrest cell cycle despite their interaction with p27kip1, leading to the interpretation that in primary cells, cyclin D-cdk4 action was not limited to p27kip1 sequestration. 28 Similarly, overexpression of p27kip1 decreases cdk4 activity in density growth inhibition of fibroblasts. 29 Consistent with this report, we propose that high levels of p27kip1 in B-CLL cells inhibit cdk4 activity and contribute to the cell cycle arrest. Various models have been suggested for role of p27kip1 in apoptosis. Reports have shown a role for p27kip1 as an apoptosis inducer [30] [31] [32] or as a protector. [33] [34] [35] It is noteworthy that most of the experimental models strongly supporting a role of p27kip1 as apoptosis inducer are based on the consequences of the overexpression of ectopic p27kip1 in actively proliferating cells. On the other hand, the protective role of p27kip1 against apoptosis has been observed in primarily nonproliferating cells. These latter results are in concordance with our experimental data in B-CLL cells and support the interpretation that p27kip1 might coordinate an exit from the cell cycle that is essential for cell survival under stress conditions. Sensitivity of nonproliferating cells such as B-CLL cells to cytotoxic agents is limited. In this study, we have provided evidence that p27kip1 decrease after fludarabine exposure was a consequence of caspase cleavage. Caspases have been implicated in fludarabine-induced apoptosis. 16, 17 The activation of caspase-3 after exposure of B-CLL cells to fludarabine is reflected by the cleavage of the PARP protein. Caspases have been implicated in cleavage of several cell cycle regulatory proteins including p27kip1, as well as p21 and pRb during apoptosis, 18, 24 but the timing and the consequences of this cleavage are highly variable from one model to another. Appearance of the 23 kDa fragment of p27kip1 was strictly associated with the apoptotic process. Notably, it was not specific to fludarabine action as it was also noted during spontaneous apoptosis or after exposure to other proapoptotic drugs such as steroids.
Clipping of p27kip1 by caspases under stress conditions has been demonstrated previously in a myeloid cell line during the apoptotic process following exposure to cytotoxic agents. 36 In a human myeloma cell line, after induction of G1 arrest by DMSO, p27kip1 cleavage preceded any evidence of apoptosis. 20 In B-CLL cells, the p23 fragment appeared as soon as 6 h after fludarabine exposure, when fewer than 10% cells had undergone apoptosis as evidenced by MTT and TUNEL assays. The first appearance of p23 truncated form was concomitant with the onset of PARP cleavage. Caspase-dependent cleavage of pRB has been noted as an early step in the apoptosis pathway.
19,24 However, we observed that the first evidence for pRb cleavage in B-CLL cells was detected after 24 h exposure to fludarabine exposure. This suggests that p27kip1 cleavage is an early event during the apoptotic process in B-CLL cells, and precludes the interpretation that p27kip1 cleavage could be a late consequence of unspecific degradation by caspases.
In B-CLL cells where p23 was detected after exposure to fludarabine, we found substantial cdk4 activity contrasting with an undetectable activity in untreated cells. In every case examined, the presence of p23 always coexisted with an increase in cdk4 activity. This cdk4 activity did not induce any cell cycle progression, as suggested by the absence of subsequent p130 and pRb phosphorylation, conversely to what was observed in neurons where cdk4 activity in apoptotic neurons was followed by pRb phosphorylation. 37 The study of the subcellular localization of these proteins allowed to show that in B-CLL cells, most of cyclin D2 and cdk4 were present in the cytoplasm. This localization allowed their interaction with p27kip1, also predominantly cytoplasmic. After fludarabine exposure, cdk4 appeared restricted to the cytoplasm, and p23 was found to interact effectively with cdk4. The amount of p27kip1 associated with cdk4 appeared to decrease over time while p23 was increasingly present in the complexes. The presence of p23 in complexes with cdk4 was concomitant of the (a) Expression of p27kip1 and the p23 clipped form was studied in three different B-CLL samples before (D0) and after a 3-day (D3) fludarabine exposure. The cdk4 activity was assessed in the same samples by the ability to phosphorylate GST-Rb. (b) Separate cytoplasmic (C) and nuclear (N) extracts were Western blotted with anti-cdk4 antibody (upper membrane) or immunoprecipitated with anti-cdk4 antibody followed by kinase reaction (lower membrane) using GST-Rb as a substrate. (c) B-CLL sample was cultured in medium alone or exposed to 5 Â 10 À6 M fludarabine for 24 or 48 h fludarabine. Whole-cell extracts were immunoprecipitated with anti-cdk4 antibody and subjected to Western blotting with an antibody recognizing the Nterminal portion of p27kip1.
p27kip1 cleavage during apoptosis of B-CLL cells L Sanhes et al onset of cdk4 activity. After fludarabine exposure, cdk4 activity was detected exclusively in the cytoplasmic extracts. Therefore, this activity was unavailable to phosphorylate the key nuclear substrates such as p130 and pRb necessary to get advancement in the cell cycle. No other target than pocket proteins have been identified for cdk4 until now. 38, 39 As various targets are known for all other cyclin-cdk complexes, it is conceivable that other targets exist for cdk4 as well. But the potential role of a cytoplasmic cdk4 activity in the apoptotic process remains to be elucidated. This possibility is consistent with evidence in various models that proteins that normally play a role in cell cycle progression may contribute to apoptosis in a cellular environment unfavorable to proliferation. Decrease in p27kip1 expression by caspase cleavage may be a key step in chemotherapy-induced apoptosis in B-CLL.
